Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 8(1): 13766, 2018 09 13.
Artigo em Inglês | MEDLINE | ID: mdl-30214009

RESUMO

The rapid decline in fertility that has been occurring to high-producing dairy cows in the past 50 years seems to be associated with metabolic disturbances such as ketosis, supporting the need for research to improve our understanding of the relations among the diet, metabolism and embryonic development. Recently, the ketone body ß-hydroxybutyrate (BOHB) was demonstrated to be a potent inhibitor of histone deacetylases (HDACs). Herein, we performed a series of experiments aiming to investigate the epigenetic effects of BOHB on histone acetylation in somatic cells, cumulus-oocyte complexes (COCs) and somatic cell nuclear transfer (SCNT) embryos. Treatment with BOHB does not increase histone acetylation in cells but stimulates genes associated with ketolysis and master regulators of metabolism. We further demonstrated that maturing COCs with high levels of BOHB does not affect their maturation rate or histone acetylation but increases the expression of PPARA in cumulus cells. Treatment of somatic cell nuclear transfer zygotes with BOHB causes hyperacetylation, which is maintained until the blastocyst stage, causing enhanced FOXO3A expression and blastocyst production. Our data shed light on the epigenetic mechanisms caused by BOHB in bovine cells and embryos and provide a better understanding of the connection between nutrition and reproduction.


Assuntos
Ácido 3-Hidroxibutírico/farmacologia , Embrião de Mamíferos/citologia , Desenvolvimento Embrionário/efeitos dos fármacos , Fertilidade/fisiologia , Inibidores de Histona Desacetilases/farmacologia , Oócitos/metabolismo , Ácido 3-Hidroxibutírico/biossíntese , Ácido 3-Hidroxibutírico/genética , Acetilação , Animais , Blastocisto/citologia , Bovinos , Linhagem Celular , Células do Cúmulo/metabolismo , Feminino , Proteína Forkhead Box O3/biossíntese , Regulação da Expressão Gênica no Desenvolvimento , Células HEK293 , Inibidores de Histona Desacetilases/metabolismo , Histona Desacetilases/metabolismo , Histonas/metabolismo , Humanos , Técnicas de Transferência Nuclear , Estresse Oxidativo/efeitos dos fármacos , PPAR alfa/biossíntese , Gravidez
2.
Genet Mol Res ; 14(4): 14469-78, 2015 Nov 19.
Artigo em Inglês | MEDLINE | ID: mdl-26600505

RESUMO

Intramuscular fatty acid (FA) is related to meat qualities such as juiciness, tenderness, palatability, and shear force. PPARα plays an important role in lipid metabolism in the liver and skeletal muscle. This study investigated FA composition in yaks and cattle, in order to ascertain whether a correlation between PPARα signal pathway genes as candidate genes and meat FA composition in yaks and cattle exists. Statistical analyses revealed that levels of monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA) in yaks were significantly higher than those in cattle (P < 0.01), whereas saturated fatty acid (SFA) levels were significantly lower than those in cattle (P < 0.05). The mRNA expression levels of FABP4 (P < 0.05), SCP2 (P < 0.05), and APOA1 (P < 0.01) in yaks were significantly lower than those in cattle. However, LPL expression in yaks was significantly higher than that in cattle (P < 0.05). In yaks, the expression levels of FABP3 (P < 0.05) and LPL (P < 0.01) were negatively correlated with MUFA, and those of FABP4 and SCD were positively correlated with PUFA (P < 0.01). In cattle, the mRNA level of PLTP was positively correlated with SFA (P < 0.05), and LPL was positively correlated with MUFA (P < 0.05). These results suggest that these genes may participate in the regulation and control of intramuscular FA metabolism in yaks, so they could be used as candidate markers to improve yak meat quality.


Assuntos
Ácidos Graxos/metabolismo , Carne , Músculo Esquelético/metabolismo , PPAR alfa/biossíntese , Animais , Bovinos , Ácidos Graxos/genética , Regulação da Expressão Gênica , Metabolismo dos Lipídeos/genética , PPAR alfa/genética , RNA Mensageiro/biossíntese , Transdução de Sinais/genética
3.
PLoS One ; 9(12): e113739, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25462161

RESUMO

BACKGROUND/AIMS: Experimental and clinical studies have shown the direct toxic effects of cigarette smoke (CS) on the myocardium, independent of vascular effects. However, the underlying mechanisms are not well known. METHODS: Wistar rats were allocated to control (C) and cigarette smoke (CS) groups. CS rats were exposed to cigarette smoke for 2 months. RESULTS: After that morphometric, functional and biochemical parameters were measured. The echocardiographic study showed enlargement of the left atria, increase in the left ventricular systolic volume and reduced systolic function. Within the cardiac metabolism, exposure to CS decreased beta hydroxy acyl coenzyme A dehydrogenases and citrate synthases and increased lactate dehydrogenases. Peroxisome proliferator-activated receptor alpha (PPARα) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) were expressed similarly in both groups. CS increased serum lipids and myocardial triacylglycerols (TGs). These data suggest that impairment in fatty acid oxidation and the accumulation of cardiac lipids characterize lipotoxicity. CS group exhibited increased oxidative stress and decreased antioxidant defense. Finally, the myocyte cross-sectional area and active Caspase 3 were increased in the CS group. CONCLUSION: The cardiac remodeling that was observed in the CS exposure model may be explained by abnormalities in energy metabolism, including lipotoxicity and oxidative stress.


Assuntos
Cardiomiopatias/sangue , Miocárdio/metabolismo , Estresse Oxidativo , Fumar/efeitos adversos , Animais , Cardiomiopatias/induzido quimicamente , Cardiomiopatias/patologia , Citrato (si)-Sintase/biossíntese , Ecocardiografia , Enoil-CoA Hidratase/biossíntese , Lactato Desidrogenases/biossíntese , Metabolismo dos Lipídeos/efeitos dos fármacos , Lipídeos/sangue , Miocárdio/patologia , Estresse Oxidativo/efeitos dos fármacos , PPAR alfa/biossíntese , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo , Ratos , Fatores de Transcrição/biossíntese , Triglicerídeos/sangue
4.
Life Sci ; 82(15-16): 876-83, 2008 Apr 09.
Artigo em Inglês | MEDLINE | ID: mdl-18374364

RESUMO

The experiments performed in this report were designed to investigate the mechanisms involved in the metabolic alterations associated with orotic acid-induced hepatic steatosis and the effect of fenofibrate, a stimulant of peroxisome proliferators-activated receptor alpha (PPARalpha), on these alterations. Male Wistar rats were divided into three experimental groups: 1) fed a balanced diet (C); 2) fed a balanced diet supplemented with 1% orotic acid (OA); 3) fed OA diet containing 100 mg.kg(-1) bw.day(-1) fenofibrate (OA+F), for 9 days. Administration of OA to rats induced significant increase in the hepatic total lipids content, marked microvesicular steatosis and decrease in plasma lipids concentrations compared to control group. Fenofibrate treatment prevented fatty liver induction, caused an additional reduction on plasma lipids concentrations and caused a 40% decrease in the lipogenic rate in adipose tissue. The results also showed a 40% increase in lipoprotein lipase (LPL) activity in adipose tissue from OA treated group and fenofibrate administration induced a 50% decrease in LPL activity. The liver mRNA expression of PPARalpha and ACO (acyl CoA oxidase) were 85% and 68% decreased in OA group when compared to control, respectively. Fenofibrate treatment increased the PPARalpha and ACO expressions whereas the CPT-1 (carnitine palmitoyl transferase-1) expression was not altered. Our results have shown that fenofibrate treatment decreases the hepatic lipid content induced by OA which is mediated by an important increase in fatty acid oxidation consequent to an increase in hepatic mRNA expression of PPARalpha and ACO.


Assuntos
Fenofibrato/uso terapêutico , Insuficiência Hepática/induzido quimicamente , Insuficiência Hepática/prevenção & controle , Hipolipemiantes/uso terapêutico , Ácido Orótico/antagonistas & inibidores , Ácido Orótico/toxicidade , Acil-CoA Oxidase/biossíntese , Adipócitos/efeitos dos fármacos , Adipócitos/metabolismo , Agonistas Adrenérgicos beta/farmacologia , Animais , Separação Celular , Dieta , Insuficiência Hepática/patologia , Hipoglicemiantes/farmacologia , Insulina/farmacologia , Isoproterenol/farmacologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Lipídeos/biossíntese , Lipólise/efeitos dos fármacos , Lipase Lipoproteica/metabolismo , Fígado/patologia , Masculino , PPAR alfa/biossíntese , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa
5.
Dig Dis Sci ; 52(12): 3448-54, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17394061

RESUMO

YHK has antioxidant properties, has a hypoglycemic effect, and may reduce plasma lipid levels. In this study, we examined the hepatic expression of PPAR-alpha and -gamma and MTP in ob/ob mice receiving or not receiving YHK. Ob/ob mice were assigned to receive oral YHK (20 mg/kg/day) fed solution (methionine/choline-deficient [MCD] diet+YHK group) or vehicle (MCD group) by gavage for 4 weeks. Liver fragments were collected for histologic examination and mRNA isolation. PPAR-alpha and -gamma and MTP gene expression was examined by RT-qPCR. YHK treatment was associated with NASH prevention, weight loss, and reduction of visceral fat and of serum concentrations of aminotransferases in comparison to the MCD group. YHK promoted an increment in PPAR-alpha and MTP and a decrement in PPAR-gamma mRNA contents. These findings suggest that modulation of PPAR-alpha and -gamma and MTP RNA expression may be implicated in the protective effect of YHK in experimental NASH, limiting hepatocyte lipid accumulation.


Assuntos
Proteínas de Transporte/genética , Fígado Gorduroso/metabolismo , Expressão Gênica/genética , PPAR alfa/genética , PPAR gama/genética , Preparações de Plantas/uso terapêutico , RNA Mensageiro/genética , Animais , Proteínas de Transporte/biossíntese , Proteínas de Transporte/efeitos dos fármacos , Modelos Animais de Doenças , Progressão da Doença , Fígado Gorduroso/tratamento farmacológico , Fígado Gorduroso/genética , Expressão Gênica/efeitos dos fármacos , Hepatócitos/metabolismo , Hepatócitos/patologia , Masculino , Camundongos , Camundongos Obesos , Microssomos Hepáticos , PPAR alfa/biossíntese , PPAR alfa/efeitos dos fármacos , PPAR gama/biossíntese , PPAR gama/efeitos dos fármacos , Fitoterapia/métodos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA